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the acute treatment of migraine
Stephanie J. Nahas1, Nada Hindiyeh2, Deborah I. Friedman3, Nada Elbuluk4, Donald J. Kellerman5* ,
Pamela K. Foreman5 and Peter Schmidt5

Abstract
Objective: To determine the long-term safety and tolerability profile of M207 in the acute treatment of migraine.
Background: M207 is an investigational microneedle-based system for intracutaneous delivery of zolmitriptan for
the treatment of migraine attacks. Following on the positive results of a Phase 2/3 placebo-controlled efficacy study
(ZOTRIP), this study was designed to evaluate the safety of this novel product during repeated use for the
treatment of migraine attacks.
Methods: In this 6–12 month open-label, multicenter observational study, participants used an eDiary to record
headache symptoms and adverse events at specified intervals up to 48 h following treatment of a qualifying attack
with M207 3.8 mg (intracutaneous zolmitriptan). Participants underwent clinical evaluations at specified intervals up
to 12 months.
Results: Among 335 participants who treated ≥1 migraine attack, 257 completed 6 months and 127 completed 1
year of treatment. The most common reason for withdrawal from the study was a low frequency of reported
attacks post randomization. Overall, 5963 migraine attacks were treated. Most participants (96%) experienced at
least 1 adverse event, the vast majority of which concerned the application site, and > 95% of which were mild.
Fifteen participants (4%) withdrew due to adverse events; 4 withdrew due to 7 application site reactions, 6 of which
were mild.
Participants achieved pain freedom in 2477/5617 (44%) of attacks, most bothersome symptom freedom in 3315/
5330 (62%) of attacks, and pain relief 2 h post-dose in 4552/5617 (81%) of attacks. Sustained pain freedom 2–24 h
was seen in 1761/4698 (38%) of attacks, and 2–48 h in 1534/4429 (35%) of attacks.
Conclusions: The majority of participants experienced cutaneous adverse reactions such as application site erythema,
swelling, and bleeding, and most reactions were scored as mild. These results are consistent with what was observed
in the single migraine attack treatment ZOTRIP trial indicating that M207 is well tolerated in the setting of longer-term
repeated use. Efficacy findings were also similar to those in the ZOTRIP trial.
Trial registration: Clinicaltrials.gov on September 13, 2017 (NCT03282227).
Keywords: Migraine, M207, Microneedle, Intracutaneous
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Background
M207 is an investigational microneedle-based system for
intracutaneous delivery of zolmitriptan for the treatment
of migraine attacks (Fig. 1). In a phase 1 trial, M207 provided faster absorption (Tmax of 15–20 min) with a greater
2-h exposure than oral zolmitriptan [1]. In a Phase 2b/3,
double-blind, placebo-controlled trial (N = 365) in which
M207 3.8 mg was used to treat a single migraine attack
(ZOTRIP, NCT02745392), 2-h pain freedom was achieved

Fig. 1 M207 system for zolmitriptan delivery. Table adapted from
Reference [1], published under CC BY-NC-ND license
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by 41.5% of those on treatment compared to 14.3% of
those on placebo [2]. Two-hour freedom from most
bothersome symptom (MBS, i.e., photophobia, phonophobia, or nausea) was achieved by 68.4% of those on treatment compared with 42.9% of those on placebo [2]. M207
was well-tolerated in this trial, with 51.8% of M207treated and 18.1% of placebo participants experiencing
treatment emergent adverse events (TEAEs), the vast majority of which were considered mild [2]. A considerable
percentage reported application site redness (26.5% in the
M207 group and 10.8% in the placebo group) and bruising
(14.5% M207 and 3.6% placebo); both were mild and transient in most participants.
Although microneedling systems are commonly used
in dermatology, this was the first combination drugdevice therapeutic microneedle system to reach Phase 3
of clinical development. Because the product is intended
for repeated use in the outpatient setting, a long-term
safety study was undertaken to assess the tolerability of
M207 when used to treat migraine attacks repeatedly
over a six- to twelve-month period. To assess application
site reactions in real-time in the at-home setting, we utilized an eDiary to prompt self-assessments after every
patch application. Participants were seen periodically by
investigators, who examined and systematically scored
patch application sites, and were queried about any nonskin-related adverse events they experienced.
This combination of solicited, participant-reported,
real-time assessment of application site observations,
investigator-assessments, and conventional adverse event
assessment was incorporated as a rigorous design for
evaluating the safety and tolerability of this new, unique
drug delivery system. We report here the methodology
and key findings from this study that support a wellcharacterized safety profile.

Methods
This was a 6–12 month open-label, multicenter study
conducted in the United States to assess the long-term
safety and efficacy of M207 in the treatment of migraine
attacks (NCT03282227). The primary outcome measure
was the percentage of participants experiencing treatment emergent adverse events (TEAEs) over 12 months.
Secondary outcomes included the percentage of migraine attacks for which pain freedom and MBS freedom
were achieved at 2 h post-dose, and the percentage for
which pain relief was achieved at 2 h post-dose.
The protocol was approved by the Copernicus (Cary,
NC) and individual investigator site Institutional Review
Boards. Potential participants provided written informed
consent. Participants 18–75 years of age were eligible if
they had a ≥ 1-year history of episodic migraine (according to ICHD-3 criteria) with onset prior to 50 years of
age. Per history, participants must have experienced
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between 2 and 8 migraine days per month during the 6month period prior to screening and may have had no
more than 15 headache days per month.
The study consisted of a screening period, a run-in
period of 2–3 weeks to determine eligibility, and a treatment period of up to 12 months. Following consent and
screening, participants were issued an eDiary to record
attack symptoms and adverse events (AEs), including
skin reactions. Enrollees were eligible for treatment if
they experienced at least 1 qualifying migraine attack
and no more than 7 headache days during the run-in
period. A qualifying migraine attack must have had at
least two of the following: unilateral location, pulsating
quality, moderate or severe pain intensity, interference
with routine physical activity. In addition, the headache
must have been accompanied by nausea or vomiting, or
both photophobia and phonophobia.
During the treatment period, M207 was applied to the
upper arm to self-administer a single dose of 3.8 mg of
zolmitriptan as two 1.9-mg patches to treat each qualifying migraine attack. The second patch was applied next
to the first one, and both were worn simultaneously for
30 min. Participants were instructed to use the eDiary to
record migraine symptoms and application site observations pre-dose, and 30 min, 2 h, 12 h, 24 h, and 48 h
post-dose. They were prompted by their eDiary to report
whether bleeding was present (at 30 min only), and if
erythema, edema, or bruising were present at the time of
patch removal (30 min), and 2, 12, 24, and 48 h postdose. Questions about pain or itching at the application
site were asked at 48 h post-dose. A total of 18 questions
were asked with responses recorded after each treated
attack. Participants received a reference card to help
them grade the application site findings on a 0–3 scale
using images from preclinical studies. Any self-reported
scores above 0 were reported as adverse events.
Migraine prophylaxis medications were allowed if participants had taken a stable dose for at least 30 days
prior to screening and with no changes during the study.
Aspirin, acetaminophen, nonsteroidal anti-inflammatory
drugs, and other medications taken specifically for migraine symptoms were prohibited on the day of a confirmed migraine attack prior to M207 application and
for 2 h after patch application.
Participants underwent clinical evaluation, including
skin assessments, at months 1, 2, 3, 6, 9, and 12 of the
treatment period, and a safety evaluation 2 weeks after
discontinuation. Erythema, edema, and bruising were
assessed by the investigator using the rating scale of
none, mild (present over ≤25% of the application area),
moderate (present over ≥26% to ≤50% of the application
area), and severe (present over > 50% of the application
area). Enrollees were queried about AEs and new concomitant medication use.
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Efficacy assessments at 30 min, 2, 12, 24, and 48 h
post-dose included the proportion of attacks with pain
freedom, the proportion with freedom from a participant’s specified most bothersome migraine-associated
symptom, and the proportion with pain relief. The primary timepoint of interest for efficacy was 2 h post-dose.
Sustained pain freedom for 2–24 h and 2–48 h was also
determined.
Statistics

Descriptive statistics were used to assess demographics,
AEs (from verbal reports as well as eDiary), and headache symptom responses. Missing data were not imputed; percentages displayed are out of the number of
patients or attacks with data. To ensure adequate exposure to M207 to evaluate safety, the predefined goal for
enrollment was a sufficient number of participants such
that at least 150 participants treated an average of at
least 2 attacks per month for 6 months, and at least 50
treated an average of at least 2 attacks per month for 12
months. All statistical tabulations and analyses were
done using SAS® Version 9.4 or higher.

Results
A total of 490 individuals were screened for participation
in the study, and 342 were enrolled. Among them, 335
treated at least one migraine attack (safety population).
Two hundred fifty-seven participants completed 6
months in the trial, and 127 participants completed 1
year of treatment. The most common reasons for not
completing the trial were not having an average of 2
qualifying migraine attacks per month (n = 79) and
sponsor’s decision to end the trial once participation
goals had been achieved (n = 60). Fifteen participants
(4.5%) withdrew from the study due to an AE.
The demographics of the study population were similar to many reported migraine trials. The mean age was
42.9 years, 88.7% of subjects were women, 79% were
Caucasian, and 16% were Black or African American.
At baseline, photophobia was prespecified as the MBS
in 51.9%, phonophobia in 23.2%, and nausea in 24.8%.
The average (standard deviation) number of treatments per month for all participants was 1.8 (0.91). Related to pre-defined participation goals, 162 participants
treated on average at least 2 migraine attacks per month
for 6 months, and 89 treated on average at least 2 migraines per month for 12 months. A total of 96 participants treated at least 25 migraine attacks and had posttreatment assessments. Overall, 5945 migraine attacks
were treated and had at least one post-treatment assessment. In total, participants were prompted by the eDiary
approximately 98,000 times to record their application
site observations. Missing post-dose data rates for eDiary
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responses were as follows: 4.1% at 30 min, 5.5% at 2 h,
11.6% at 12 h, 8.7% at 24 h, and 10.1% at 48 h.
The AEs occurring in ≥2% of participants are
shown in Table 1. The most common adverse events
were related to the application site, and all were recorded in the participants’ eDiaries except for one instance of bruising and one instance of application site
pain. Investigators’ assessments in the clinic revealed
a similar pattern, though with lower incidences. Investigators also reported discoloration at the application site at least once in 16% of participants, and this
was the most common adverse event not captured by
the eDiary. Discoloration tended to be more frequent
in those with higher Fitzpatrick skin types ranging
from 7% in those with type 1 or 2 to 31% in those
with type 4, and 18% in those with type 5 or 6. Results were consistent across all other subgroups analyzed. Regarding reactions of potential concern, in 2
participants, vesicles at the application site were
noted. One case was participant-reported, and the
duration was 1 day. The second case was noted by
the investigator at a study visit, and the vesicle resolved in 4 days.
More than 95% of application site reactions were rated
as mild; none were rated as severe. More than 80% of
swelling and redness incidents were rated as zero by 48
h post-application. No skin observations warranted referral to a dermatologist. For participants who treated at
least 25 attacks (n = 96) over the course of the study, the
frequency or severity of site reactions did not change

Table 1 Treatment-Emergent Adverse Events (TEAEs) Reported
in ≥2% of Participants (Safety Population, N = 335
SOC Preferred Term

All Adverse Events
n (%) of Participants

Application site erythemaa

316 (94.3)

a

Application site swelling

296 (88.4)

Application site haemorrhagea

225 (67.2)

a

Application site bruise

194 (57.9)

Application site paina

81 (24.2)

Application site discolouration

a

Application site pruritusa
a

53 (15.8)
52 (15.5)

Application site oedema

8 (2.4)

Upper respiratory tract infection

28 (8.4)

Sinusitis

13 (3.9)

Nausea

9 (2.7)

Viral upper respiratory tract infection

7 (2.1)

A participant who experienced multiple events within a SOC was counted only
once for that SOC
Adverse events were coded with MedDRA v 20.0
SOC System Organ Class
a
Adverse Event was considered possibly or probably drug-related
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appreciably from the 1st to the 5th to the 15th or to the
25th attack.
Table 2 shows AEs that led to withdrawal from the
study. All events occurred in the first 6 months of the
study, and 4 participants withdrew due to application
site reactions. Of the 7 total reactions, 6 were mild and
all lasted less than 1 day.
Neurological adverse reactions that are often associated with triptans were reported by a small percentage
of participants in this study; no event was reported in
2% or more of participants. Dizziness was reported by
1.8%. Other typical triptan-associated adverse events
such as paresthesia and jaw tightness were reported in
1–1.5%. There was one serious and possibly treatmentrelated adverse event in the trial; one participant became
pregnant and had received one dose of study drug. Although unconfirmed, she may have been pregnant at the
time of her dose. She reported by telephone that a birth
defect in the unborn fetus had been observed on ultrasound. She declined to come to the study center to be
seen for further evaluation, and subsequent attempts to
reach her were unsuccessful.
No other serious treatment-related AEs or adverse
events of special interest (scarring or any site reactions
requiring further evaluation or care) were reported.
There were no reported infections at the application site.
Efficacy

Outcomes for key efficacy variables are shown in Fig. 2.
The proportion of attacks from which participants
achieved pain freedom, MBS freedom, and pain relief at
2 h post-dose are very similar to what was observed in
the pivotal ZOTRIP trial [2]. The proportion for which
pain freedom was sustained was similar, with 38% experiencing pain freedom from 2 to 24 h and 35% from 2
to 48 h. Similarly, the percentage of attacks that had sustained pain relief 2–24 h was 70%, and for 2–48 h it was
65%. Rates for associated symptom freedom at 2 h post
dose of qualifying migraine attacks were as follows: nausea 82%, photophobia 61%, and phonophobia 63%. Participants were instructed not to take any rescue
medications in the first 2 h post-dose; however, rescue
medication was taken within this interval in 3.6% of
attacks.

Discussion and conclusions
Safety and tolerability findings in this long-term study
were similar to those seen in the previously conducted
pivotal single attack ZOTRIP trial [2]. These findings are
also consistent with the side effect profile that has been
seen with dermatologic uses of microneedling [3, 4].
Specifically, microneedle application is associated with
transient redness, swelling, and sometimes bruising, that
resolves over hours to days after application. In some

Nahas et al. The Journal of Headache and Pain

(2021) 22:37

Table 2 Number of Participants with Treatment Emergent
Adverse Eventsa leading to Study Drug Withdrawal (Safety
Population, N = 335)
Adverse Event Preferred Termb

M207 3.8
mg
n (%)

Amenorrhoeac

1 (0.3)

Anxietyc

2 (0.6)

Application site haemorrhage

1 (0.3)

Application site pain

1 (0.3)

Application site swelling

1 (0.3)

Application site pain, erythema, haemorrhage, and
swelling

1 (0.3)

Breast cancer stage IIc

1 (0.3)

Dysphagia

1 (0.3)

Facial Pain

1 (0.3)

Hangover

1 (0.3)

Migraine

1 (0.3)

Nausea

1 (0.3)

Paraesthesia and somnolence

1 (0.3)

Pharyngeal oedema

1 (0.3)

a

Treatment emergent adverse events are defined as any new AE that started
after first patch application
b
Adverse events were coded with MedDRA v 20.0
c
Not Related

individuals, there can be temporary pigmentary changes
that resolve typically over time. The microneedles for
M207 are 340 μm in length and appear to penetrate less
than 150 μm [5], which probably contributes to the transient nature of the application site effects and the lack of
infections seen at the application sites. Other than

a
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application site TEAEs, the safety and tolerability were
as expected with the use of zolmitriptan [6, 7].
Although application site TEAEs were generally mild,
they were reported in the majority of participants in this
12-month study. Notably, investigators’ assessments
tended to indicate a lower incidence; for example, the
frequency of redness was 26% lower. This observation
likely reflects, at least in part, the timing of the observations, as the events may have resolved by the time a participant visited the clinic. However, it should also be
considered that adverse event reporting in this trial was
solicited, i.e. collected via structured responses in the
eDiary at 5 separate time points after patch application.
This approach has the advantage of enhancing the
consistency and detection of a safety signal but may also
lead to inflation of reporting due to the suggestive nature of the questioning. This phenomenon has been documented in other trials in which AEs reported using a
structured questionnaire were nominally similar but substantially more frequent than when participants were
not asked about specific AEs [8, 9].
Photographs from preclinical studies were provided to
participants to assist in assessing application site skin effects. Except for observations of concern, photography
or other imaging methods were not used routinely to
capture application site findings in this trial. This decision was made in accordance with discussions with the
Dermatology Division at the FDA, and at least in part
due to challenges associated with capturing and standardizing images.
The proportion of attacks for which pain freedom, MBS
freedom, and pain relief were achieved at 2 h post-dose
was similar to what was seen in the ZOTRIP trial [2].

b

Fig. 2 Key Efficacy Outcomes. a Percentage of headaches for which subjects experienced freedom from headache pain and/or most bothersome
other migraine-associated symptom at 2 h post-dose. Results for MBS-freedom are presented only for those whose MBS was present pre-dose.
Numbers below bars indicate number of headaches assessed. MBS: Most Bothersome Symptom. b Percentage of headaches for which subjects
had sustained pain freedom from 2 to24 hours and from 2 to 48 h post-dose. Numbers below bars indicate number of headaches assessed
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Sustained pain freedom over the periods 2 to 24 h or 2 to
48 h was also similar (38% vs 32% for 2 to 24 h for this
trial, and 35% vs 27% for 2 to 48 h for the ZOTRIP trial).
The adverse event profile of M207 is primarily related
to mild skin reactions (particularly redness) that occur at
the application site in a high percentage of participants.
Other adverse events seen were those typically associated with zolmitriptan administration by other routes,
and the rate of occurrence did not appear to be higher
than with other zolmitriptan products.
Potential limitations of this study include the subjective nature of severity of participant-reported applications
site reactions as well as the lack of contemporaneous assessment by investigators.
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